Last reviewed · How we verify
NCT07057843
Sequential Nutrition Intervention for Pancreatic Cancer Patients Undergoing CyberKnife Radiotherapy
NA trial testing Sequential Nutrition Intervention in Pancreatic Cancer in 100 participants. Completed in 30 July 2024.
30 July 2024
Quick facts
| Lead sponsor | The First Hospital of Hebei Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 June 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sequential Nutrition Intervention
- Enteral Nutrition Emulsion — full drug profile →
- Routine Nutritional Intervention
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
The First Hospital of Hebei Medical University
Who can join
60 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the clinical value of a structured nutritional support program for patients with pancreatic cancer undergoing CyberKnife radiotherapy. The study compares a sequential nutrition intervention, guided by nutritional risk screening, against routine nutritional advice. The goal is to determine if the structured intervention can better improve patients' nutritional status, immune function, and quality of life, while reducing the rate of postoperative complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07057843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other The First Hospital of Hebei Medical University trials
Trials by the same sponsor.
- NCT07467603 — ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients · NA · completed
- NCT07243444 — Home-Based Versus Center-Based Cardiac Rehabilitation After CABG Surgery · NA · completed
- NCT07047534 — EEG-Triggered rTMS and Group Therapy for Adolescents With Depression and Self-Harm · NA · completed
- NCT07232693 — Telerehabilitation vs. Center-Based Rehab for Psychological Well-being After CABG · NA · completed
- NCT06344390 — Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07057843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Hebei Medical University
- Last refreshed: 10 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07057843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing